Predominance of β-cell neogenesis rather than replication in humans with an impaired glucose tolerance and newly diagnosed diabetes

S. Yoneda, S. Uno, H. Iwahashi, Y. Fujita, A. Yoshikawa, J. Kozawa, K. Okita, D. Takiuchi, Hidetoshi Eguchi, H. Nagano, A. Imagawa, I. Shimomura

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Context: A decrease in pancreatic β-cell mass is involved in the development of type 2 diabetes. Objective: The purpose of this study was to evaluate the β-cell mass and the incidence of β-cell neogenesis, replication, and apoptosis at both the prediabetic and diabetic stages. Methods: We conducted a cross-sectional study of pancreatic tissues obtained from 42 patients undergoing a pancreatectomy who were classified into 4 groups: normal glucose tolerance (n = 11), impaired glucose tolerance (n = 11), newly diagnosed diabetes (n = 10), and long-standing type 2 diabetes (n = 10). Results: The relative β-cell area decreased and the β-cell apoptosis increased during the development of diabetes. The number of single and clustered β-cells, some of which coexpressed nestin, increased in the patients with impaired glucose tolerance and newly diagnosed diabetes. The prevalence of cells positive for both insulin and glucagon or somatostatin also increased in these patients compared with those with normal glucose tolerance. These double-positive cells were mainly localized in single and clustered β-cells, rather than large islets, and were also positive for Pdx1 or Ngn3. The percentage of insulin-positive cells embedded within ducts increased in the impaired glucose tolerance group. There were no significant differences in the incidence of cells positive for both insulin and Ki67 among the groups. Conclusions: These results suggest that β-cell neogenesis, rather than replication, predominates during impaired glucose tolerance and newly diagnosed diabetes in humans and may serve as a compensatory mechanism for the decreased β-cell mass.

Original languageEnglish
Pages (from-to)2053-2061
Number of pages9
JournalJournal of Clinical Endocrinology and Metabolism
Volume98
Issue number5
DOIs
Publication statusPublished - May 1 2013

Fingerprint

Glucose Intolerance
Medical problems
Glucose
Insulin
Cells
Apoptosis
Nestin
Somatostatin
Glucagon
Ducts
Type 2 Diabetes Mellitus
Tissue
Pancreatectomy
Incidence

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Predominance of β-cell neogenesis rather than replication in humans with an impaired glucose tolerance and newly diagnosed diabetes. / Yoneda, S.; Uno, S.; Iwahashi, H.; Fujita, Y.; Yoshikawa, A.; Kozawa, J.; Okita, K.; Takiuchi, D.; Eguchi, Hidetoshi; Nagano, H.; Imagawa, A.; Shimomura, I.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 98, No. 5, 01.05.2013, p. 2053-2061.

Research output: Contribution to journalArticle

Yoneda, S, Uno, S, Iwahashi, H, Fujita, Y, Yoshikawa, A, Kozawa, J, Okita, K, Takiuchi, D, Eguchi, H, Nagano, H, Imagawa, A & Shimomura, I 2013, 'Predominance of β-cell neogenesis rather than replication in humans with an impaired glucose tolerance and newly diagnosed diabetes', Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 5, pp. 2053-2061. https://doi.org/10.1210/jc.2012-3832
Yoneda, S. ; Uno, S. ; Iwahashi, H. ; Fujita, Y. ; Yoshikawa, A. ; Kozawa, J. ; Okita, K. ; Takiuchi, D. ; Eguchi, Hidetoshi ; Nagano, H. ; Imagawa, A. ; Shimomura, I. / Predominance of β-cell neogenesis rather than replication in humans with an impaired glucose tolerance and newly diagnosed diabetes. In: Journal of Clinical Endocrinology and Metabolism. 2013 ; Vol. 98, No. 5. pp. 2053-2061.
@article{c53c638ab7a949b199ed14386e35b7dc,
title = "Predominance of β-cell neogenesis rather than replication in humans with an impaired glucose tolerance and newly diagnosed diabetes",
abstract = "Context: A decrease in pancreatic β-cell mass is involved in the development of type 2 diabetes. Objective: The purpose of this study was to evaluate the β-cell mass and the incidence of β-cell neogenesis, replication, and apoptosis at both the prediabetic and diabetic stages. Methods: We conducted a cross-sectional study of pancreatic tissues obtained from 42 patients undergoing a pancreatectomy who were classified into 4 groups: normal glucose tolerance (n = 11), impaired glucose tolerance (n = 11), newly diagnosed diabetes (n = 10), and long-standing type 2 diabetes (n = 10). Results: The relative β-cell area decreased and the β-cell apoptosis increased during the development of diabetes. The number of single and clustered β-cells, some of which coexpressed nestin, increased in the patients with impaired glucose tolerance and newly diagnosed diabetes. The prevalence of cells positive for both insulin and glucagon or somatostatin also increased in these patients compared with those with normal glucose tolerance. These double-positive cells were mainly localized in single and clustered β-cells, rather than large islets, and were also positive for Pdx1 or Ngn3. The percentage of insulin-positive cells embedded within ducts increased in the impaired glucose tolerance group. There were no significant differences in the incidence of cells positive for both insulin and Ki67 among the groups. Conclusions: These results suggest that β-cell neogenesis, rather than replication, predominates during impaired glucose tolerance and newly diagnosed diabetes in humans and may serve as a compensatory mechanism for the decreased β-cell mass.",
author = "S. Yoneda and S. Uno and H. Iwahashi and Y. Fujita and A. Yoshikawa and J. Kozawa and K. Okita and D. Takiuchi and Hidetoshi Eguchi and H. Nagano and A. Imagawa and I. Shimomura",
year = "2013",
month = "5",
day = "1",
doi = "10.1210/jc.2012-3832",
language = "English",
volume = "98",
pages = "2053--2061",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "5",

}

TY - JOUR

T1 - Predominance of β-cell neogenesis rather than replication in humans with an impaired glucose tolerance and newly diagnosed diabetes

AU - Yoneda, S.

AU - Uno, S.

AU - Iwahashi, H.

AU - Fujita, Y.

AU - Yoshikawa, A.

AU - Kozawa, J.

AU - Okita, K.

AU - Takiuchi, D.

AU - Eguchi, Hidetoshi

AU - Nagano, H.

AU - Imagawa, A.

AU - Shimomura, I.

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Context: A decrease in pancreatic β-cell mass is involved in the development of type 2 diabetes. Objective: The purpose of this study was to evaluate the β-cell mass and the incidence of β-cell neogenesis, replication, and apoptosis at both the prediabetic and diabetic stages. Methods: We conducted a cross-sectional study of pancreatic tissues obtained from 42 patients undergoing a pancreatectomy who were classified into 4 groups: normal glucose tolerance (n = 11), impaired glucose tolerance (n = 11), newly diagnosed diabetes (n = 10), and long-standing type 2 diabetes (n = 10). Results: The relative β-cell area decreased and the β-cell apoptosis increased during the development of diabetes. The number of single and clustered β-cells, some of which coexpressed nestin, increased in the patients with impaired glucose tolerance and newly diagnosed diabetes. The prevalence of cells positive for both insulin and glucagon or somatostatin also increased in these patients compared with those with normal glucose tolerance. These double-positive cells were mainly localized in single and clustered β-cells, rather than large islets, and were also positive for Pdx1 or Ngn3. The percentage of insulin-positive cells embedded within ducts increased in the impaired glucose tolerance group. There were no significant differences in the incidence of cells positive for both insulin and Ki67 among the groups. Conclusions: These results suggest that β-cell neogenesis, rather than replication, predominates during impaired glucose tolerance and newly diagnosed diabetes in humans and may serve as a compensatory mechanism for the decreased β-cell mass.

AB - Context: A decrease in pancreatic β-cell mass is involved in the development of type 2 diabetes. Objective: The purpose of this study was to evaluate the β-cell mass and the incidence of β-cell neogenesis, replication, and apoptosis at both the prediabetic and diabetic stages. Methods: We conducted a cross-sectional study of pancreatic tissues obtained from 42 patients undergoing a pancreatectomy who were classified into 4 groups: normal glucose tolerance (n = 11), impaired glucose tolerance (n = 11), newly diagnosed diabetes (n = 10), and long-standing type 2 diabetes (n = 10). Results: The relative β-cell area decreased and the β-cell apoptosis increased during the development of diabetes. The number of single and clustered β-cells, some of which coexpressed nestin, increased in the patients with impaired glucose tolerance and newly diagnosed diabetes. The prevalence of cells positive for both insulin and glucagon or somatostatin also increased in these patients compared with those with normal glucose tolerance. These double-positive cells were mainly localized in single and clustered β-cells, rather than large islets, and were also positive for Pdx1 or Ngn3. The percentage of insulin-positive cells embedded within ducts increased in the impaired glucose tolerance group. There were no significant differences in the incidence of cells positive for both insulin and Ki67 among the groups. Conclusions: These results suggest that β-cell neogenesis, rather than replication, predominates during impaired glucose tolerance and newly diagnosed diabetes in humans and may serve as a compensatory mechanism for the decreased β-cell mass.

UR - http://www.scopus.com/inward/record.url?scp=84877691201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877691201&partnerID=8YFLogxK

U2 - 10.1210/jc.2012-3832

DO - 10.1210/jc.2012-3832

M3 - Article

C2 - 23539729

AN - SCOPUS:84877691201

VL - 98

SP - 2053

EP - 2061

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 5

ER -